Alliancebernstein L.P. Buys 128,041 Shares of Integra LifeSciences Holdings Corporation $IART

Alliancebernstein L.P. lifted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 5.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,706,434 shares of the life sciences company's stock after purchasing an additional 128,041 shares during the period. Alliancebernstein L.P. owned 3.48% of Integra LifeSciences worth $59,514,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the business. Systematic Financial Management LP increased its position in Integra LifeSciences by 8.9% in the 1st quarter. Systematic Financial Management LP now owns 936,834 shares of the life sciences company's stock worth $20,601,000 after buying an additional 76,271 shares during the period. Hsbc Holdings PLC increased its position in Integra LifeSciences by 303.6% during the first quarter. Hsbc Holdings PLC now owns 40,323 shares of the life sciences company's stock worth $887,000 after acquiring an additional 30,331 shares during the period. Quantbot Technologies LP increased its position in Integra LifeSciences by 151.6% during the first quarter. Quantbot Technologies LP now owns 19,825 shares of the life sciences company's stock worth $436,000 after acquiring an additional 11,944 shares during the period. Wellington Management Group LLP increased its position in Integra LifeSciences by 10.4% during the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock worth $60,827,000 after acquiring an additional 259,987 shares during the period. Finally, Tejara Capital Ltd bought a new position in Integra LifeSciences during the first quarter worth $1,209,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded down $0.36 on Friday, hitting $15.12. 161,798 shares of the company were exchanged, compared to its average volume of 1,049,145. The company's 50 day moving average price is $13.58 and its two-hundred day moving average price is $15.60. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $27.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -2.31, a PEG ratio of 0.87 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same period in the previous year, the company posted $0.63 earnings per share. The company's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.